BofA lowered the firm’s price target on BioMarin (BMRN) to $85 from $97 and keeps a Buy rating on the shares. The firm, which updated its outlook for the pro-forma company ahead of the close of BioMarin’s Amicus (FOLD) deal in Q2, says its reduced target largely reflects more conservative assumptions on the Voxzogo-franchise tail.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN: